Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in NNOX.

← Back to Free Index

NNOX

Analysis as of: 2026-09-21

Nano-X Imaging Ltd.

Nanox develops multisource digital tomosynthesis imaging systems and sells related cloud workflow, AI, teleradiology, and health IT services to providers and channel partners.

ai cloud healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

A Distressed Imaging Option With Real Gates

The upside is real because a tiny revenue base could scale sharply if live imaging sites become bundled recurring contracts. But the path is unforgiving: financing, activation, reimbursement, and utilization must arrive in sequence.

Analysis

Thesis

Nanox is a financing-gated option on turning cleared imaging hardware plus workflow, radiology, and AI into a recurring imaging utility; if it solves activation and dilution discipline, a tiny revenue base can scale non-linearly, but the sequence has to work in order.

Last Economy Alignment

Moderately positive: AI helps imaging workflow, reporting, and service productivity, and low seat exposure limits pure software commoditization. But value capture still depends on regulated hardware activation, reimbursement, and capital access, while larger OEM bundles can compress pricing.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

14.0x (from 5 most recent analyses)

Reasoning

This is a survival-to-scale rerating, not a clean compounding story. The upside comes from moving from scattered deployments and services into activated sites that bundle imaging, cloud workflow, radiology reads, and AI into recurring contracts. I keep the terminal multiple below premium healthcare software because the mix should still include hardware, service labor, and financing drag.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

This is a sequence-risk equity. The company first needs share-issuance flexibility and fresh capital, then faster site approvals and activations, then proof that utilization, reimbursement, and bundled services can create durable recurring revenue. The technology is real enough for upside, but dilution, activation slippage, and stronger incumbent bundles can still stop the flywheel before it forms.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On September 17, 2026, the annual meeting lacked quorum and the authorized-share vote was pushed to September 29, making financing flexibility an even clearer near-term gate.
On September 9, 2026, the company reported first patient scans at its first Nanox Imaging Network site and said it had begun receiving insurer reimbursement for those scans.
The same September 9, 2026 update said there was no material change in systems in deployment versus prior disclosure, reinforcing that activation remains slower than headline partner growth.
September 2026 distribution announcements in New England and Costa Rica expanded channel reach, but they add pipeline more than immediate proof of recurring economics.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.33

They own a cleared imaging machine and the software and reading services around it, so AI can help them sell clinical throughput instead of a cheap app. The risk is that bigger vendors can bundle similar workflows, and if this company cannot fund and activate sites quickly, the advantage never compounds.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$4.33

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research